Background:

Accepts ubiquitin from the E1 complex and catalyzes its covalent attachment to other proteins. In vitro, in the presence or in the absence of BRCA1-BARD1 E3 ubiquitin-protein ligase complex, catalyzes the synthesis of 'Lys-48'-linked polyubiquitin chains. Does not transfer ubiquitin directly to but elongates monoubiquitinated substrate protein. Mediates the selective degradation of short-lived and abnormal proteins, such as the endoplasmic reticulum-associated degradation(ERAD) of misfolded lumenal proteins. Ubiquitinates huntingtin. May mediate foam cell formation by the suppression of apoptosis of lipid-bearing macrophages through ubiquitination and subsequence degradation of p53/TP53. Proposed to be involved in ubiquitination and proteolytic processing of NF-kappa-B; in vitro supports ubiquitination of NFKB1. In case of infection by cytomegaloviruses may be involved in the US11-dependent degradation of MHC class I heavy chains following their export from the ER to the cytosol. In case of viral infections may be involved in the HPV E7 protein-dependent degradation of RB1.

Clonality:

polyclonal

Classification:

Primary antibody

Alternative names:

DKFZp564C1216, DKFZp686J24237, E2-25K, HIP 2, HIP2, HYPG, LIG, UBE2K, Ubiquitin carrier protein, Ubiquitin protein ligase

Specificity:

Human, Mouse, Rat

Host:

Rabbit

Isotype:

IgG

Immunogen:

ubiquitin-conjugating enzyme E2K(UBC1 homolog, yeast)

Purification:

Immunogen affinity purified

Purity:

≥95% as determined by SDS-PAGE

Calculated molecular weight:

29 kDa, Observed 60 kDa

Form:

liquid

Applications:

ELISA, WB, IHC

Recommended dilution:

WB: 1:500-1:5000; IHC: 1:20-1:200

Storage:

PBS with 0.02% sodium azide and 50% glycerol pH 7.3,-20℃ for 12 months(Avoid repeated freeze / thaw cycles.)

More info:

Email: info@sobekbio.com

Orders:

Email: orders@sobekbio.com